Net Income

Strong Q1 results driven by Australian operations and a record gas compression backlog, offsetting a cautious North American drilling market.

The medical device maker posts its 14th straight growth quarter, with soaring profits and a strategic focus on the underserved bronchiectasis market.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

Andersen Group reports a 15.7% revenue jump, but IPO-related costs mask strong operational performance as the firm pursues aggressive global expansion.

As BranchOut Food preps its Q1 earnings call, investors watch to see if its patented tech and retail wins can deliver on the path to profitability.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

Resideo posted strong Q1 results with an 8% revenue jump to $1.91B, setting a positive stage for the planned separation of its ADI distribution arm.

A new national survey reveals a crisis of trust in the American workplace, with widespread fear silencing employees and ethical pressures on the rise.

A new AI-driven ecosystem promises to cut GMP media manufacturing to just 4 weeks, aiming to break a critical bottleneck in cell and gene therapy development.

Groundbreaking research suggests routine X-rays are crucial for young ACL patients to prevent growth issues and reinjury, potentially changing care standards.

A new platform by AI lab Darrow lets law firms hunt for cases and manage dockets like a portfolio, promising to unlock billions in hidden legal claims.

A Boston-area biotech is tackling a key bottleneck in drug manufacturing, promising to unlock a new generation of RNA therapeutics with its novel platform.

Wina Hanselman’s award highlights how remote triage provides a vital human touch, offering a solution to the nursing shortage in hospice and home health.

Stephen Curley takes the helm at Eagle Bancorp, signaling a strategic pivot to tackle real estate loan challenges and drive diversified growth.

Hong Kong security firm SU Group is raising $6M via a complex warrant offering, stirring investor debate on whether it's for growth or a financial lifeline.

A new 'agentic storefront' is promising 2x conversion rates by giving brands their own AI, challenging the model of ceding customer data to big tech.